A HER2-Targeting Antibody-MMAE Conjugate RC48 Sensitizes Immunotherapy in HER2-Positive Colon Cancer by Triggering the cGAS-STING Pathway

Investigators found that human epidermal growth factor receptor 2 (HER2) was present in a portion of colon cancer patients, raising the possibility of using anti-HER2 therapy. In vitro studies using colon cancer cell lines showed that RC48 effectively impeded the proliferation of HER2-positive cells, indicating its potential as a treatment for HER2-positive colon cancer.